Shots:

• The approval is based on two P-III studies evaluating the diagnostic results of Gadavist enhanced cardiac MRI to assess myocardial perfusion and late gadolinium enhancement in adult patients with CAD
• Gadobutrol-enhanced cardiac MRI demonstrated efficacy in global clinical studies and provide details about the functions of the heart muscles to support the management of patients with CAD
• Gadavist is an approved contrast agent in >100 countries including the US- EU- Japan for multiple indications i.e- CE-MRA- CE-MRI of the liver and kidneys- CNS and all body regions

Click here to read full press release/ article | Ref: Bayer | Image: Office Snapshots